Tjoapack has doubled its packaging capacity with the completion of its Netherlands facility expansion.
Tjoapack, a global pharmaceutical contract packaging organization, announced on April 13, 2022 that the expansion of its Etten-Leur facility in the Netherlands has been completed. The expansion follows an over €10 million investment into the facility. This is the company’s first investment since its acquisition of Pharma Packaging Solutions, a US healthcare packaging firm.
Tjoapack, which specializes in primary and secondary packaging of oral solids and injectables, has doubled its packaging capacity through the investment. The expansion includes the addition of 10 new production rooms and a total size increase of the facility from 8400m2 to 11,500m2. The expansion also includes three new production lines, a fully automated packaging line for vials, and two new high-speed production lines for oral solids. The facility now has a total of 18 packaging lines for blisters, vials, and bottles, with the capacity of packaging 12 million vials per year and 500 blisters per minute.
The company has also invested in increasing its warehousing and cold chain capabilities, as well as further increasing packaging capacity by the end of the year through purchasing more blister machines and a new packaging line for pre-filled syringes.
“Packaging is of course fundamental to the safe, effective delivery of virtually every pharmaceutical product,” said Boy Tjoa, managing director of Tjoapack, in a press release. “I am proud that through our expansion we can help bring even more products to market safely. We remain committed to our European headquarters and this latest investment is an important step to meeting the growing needs of our customers and assure healthcare products are usable, available, traceable, and affordable.”
Source: Tjoapack
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.